An Expanded Treatment Protocol of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Previously Treated Myeloma

Conclusion Overall, data from PANEX support regulatory approval of panobinostat plus bortezomib and dexamethasone and suggest potential tolerability benefits of subcutaneous bortezomib in this regimen. Teaser The Panobinostat Expansion (PANEX) treatment protocol (N = 39) provided access to panobinostat and gathered additional efficacy and safety data on the panobinostat-bortezomib-dexamethasone regimen before commercial availability. The findings from the study supported those that led to regulatory approval of panobinostat-bortezomib-dexamethasone. Additionally, use of subcutaneous bortezomib in PANEX had potential tolerability benefits, including a relatively low rate of peripheral neuropathy.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research